35 results on '"Zappala, Christopher"'
Search Results
2. Comparing Polymerase Chain Reaction Testing of Nasopharyngeal Swab and Lower Respiratory Tract Specimens for the Diagnosis of Pneumocystis jirovecii Pneumonia.
3. Mapping EQ5D utilities from forced vital capacity and diffusing capacity in fibrotic interstitial lung disease
4. Gastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry
5. Circadian Rhythmicity of Vital Signs at Intensive Care Unit Discharge and Outcome of Traumatic Brain Injury
6. Deep Learning–based Outcome Prediction in Progressive Fibrotic Lung Disease Using High-Resolution Computed Tomography
7. Biomarker signatures for progressive idiopathic pulmonary fibrosis
8. Temperature rhythms and ICU sleep: the TRIS study
9. Australian Idiopathic Pulmonary Fibrosis Registry: Vital lessons from a national prospective collaborative project
10. A randomised study of comfort during bronchoscopy comparing conscious sedation and anaesthetist-controlled general anaesthesia, including the utility of bispectral index monitoring
11. Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials
12. Predicting Pulmonary Fibrosis Disease Course From Past Trends in Pulmonary Function
13. Accuracy of Individual Variables in the Monitoring of Long-term Change in Pulmonary Sarcoidosis as Judged by Serial High-Resolution CT Scan Data
14. The antimicrobial effect of heparin on common respiratory pathogens
15. Comment on “The natural history of progressive fibrosing interstitial lung diseases”
16. Idiopathic pulmonary fibrosis: is all-cause mortality a practical and realistic end-point for clinical trials?
17. Aetiology and clinical phenotype still seem distant in sarcoidosis
18. Effect of Exogenous Melatonin Administration in Critically Ill Patients on Delirium and Sleep: A Randomized Controlled Trial
19. Circulating RNA differences between patients with stable and progressive idiopathic pulmonary fibrosis
20. Additional file 2: Table S2. of Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry
21. Additional file 1: Table S1. of Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry
22. Implications of the diagnostic criteria of idiopathic pulmonary fibrosis in clinical practice: Analysis from the Australian Idiopathic Pulmonary Fibrosis Registry
23. Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry
24. Disease progression at 12 months does not predict future outcomes in IPF patients: Analysis from the Australian IPF Registry
25. Determinants and outcomes of prolonged anxiety and depression in idiopathic pulmonary fibrosis
26. Health-related quality of life in idiopathic pulmonary fibrosis: Data from the Australian IPF Registry
27. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry
28. Implications of the diagnostic criteria of idiopathic pulmonary fibrosis in clinical practice: Analysis from the Australian Idiopathic Pulmonary Fibrosis Registry.
29. Disease progression in early idiopathic pulmonary fibrosis: Insights from the Australian IPF registry
30. Quality of life of patients with idiopathic pulmonary fibrosis (IPF) - What can the Australian IPF registry tell us?
31. Serum Interleukin 6 Is Predictive of Early Functional Decline and Mortality in Interstitial Lung Disease Associated with Systemic Sclerosis
32. Idiopathic Pulmonary Fibrosis: Predicting Future Disease Course From Past Trends In Pulmonary Function
33. Reconciling Healthcare Professional and Patient Perspectives in the Development of Disease Activity and Response Criteria in Connective Tissue Disease–related Interstitial Lung Diseases
34. Idiopathic pulmonary fibrosis: is all-cause mortality a practical and realistic end-point for clinical trials?
35. Biomarker signatures for progressive idiopathic pulmonary fibrosis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.